Ceretype Neuromedicine Closes Second Round of Seed Financing to Accelerate Growth
Summary
(BUSINESS WIRE)Ceretype Neuromedicine, a pioneer in the practical application and integration of functional MRI (fMRI), announced today that it has closed its second round of seed financing. Ceretypes proprietary end-to-end platform brings remarkable innovation to the previous shortcomings of traditional fMRI, unlocking a powerful tool to visualize and study brain circuitry at a scale that has not been possible before, said Cedar Street Group Managing Principal Paul Francis.Ceretype was founded in 2020 by experts in neuromedicine and brain imaging to translate years of academic research into practical tools that will transform therapeutic development and clinical care. Since its founding, Ceretype has partnered with several pharmaceutical and biotech companies to help visualize and quantitatively analyze the impact of their treatments on the functional networks within patients brains.We are grateful for our investors continued support and excitement around our groundbreaking fMRI platform. Our uniquely scalable end-to-end platform makes targeted biomarkers accessible, delivering actionable evidence to improve drug discovery and, ultimately, patient care. Through its superior technical approach and its unique ability to sub-type and classify the human brain on a neurobiological level, Ceretype offers novel, precise, biologically-based therapeutic insights.